
An AI-generated drug molecule shrank tumors in 4 of 22 mesothelioma patients in a phase-1 oncology trial for mesothelioma. The early data were presented by @MMarmarelis at the 2026 European Society for Medical Oncology Congress in Madrid. @DrugDiscoverDev spr.ly/6018By1Gun









